Twenty years ago, Andrew Moore and colleagues28 concluded on the basis of a series of simulations that “size is everything” if the samples of patients enrolled in randomized clinical trials (RCTs) are to provide credible estimates of the clinical efficacy of acute pain treatments. The results of 2 recent studies suggest that factors such as increasing placebo group response and changes in study methodologic characteristics may limit or reduce estimates of the effects of chronic pain treatments and thereby necessitate larger sample sizes for adequate statistical power to identify minimally clinically important effects.
from The Journal of Pain https://ift.tt/2o0XejA
via IFTTT
No comments:
Post a Comment